Speakers 2021

Speakers 2021

Marina DESCHAMPS

RIGHT INSTITUTE


CAR-T CELLS (I) (KURSAAL CONF ROOM)

October 14th

From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor interactions and in anti-tumor immunotherapy approaches. Based on the monitoring of the suicide gene therapy clinical trial to control Graft vs Host Disease (GvHD) has allowed me to acquire a great experience on T-cells gene therapy. Building on this experience, as the scientific responsible, I have contributed to develop a new suicide gene clinical trial based on iCasp9/Rimiducid®. This clinical trial “Side by CIDe” (ClinicalTrials.gov Identifier: NCT02849886) is approved by the French regulatory agency (ANSM) in the context of the new ATMP European regulations and is open for recruitment. The expertise acquired from gene transfer and vectorology for more than 19 years, has been naturally transposed to develop anti-tumor immunotherapy approaches based on LT reprogramming with Chimeric Antigen Receptor (CAR) or transgenic TCR (TCRtg). My involvement in the different study of gene modified T cells, and more recently in CART cells, and my scientific and technical background in the field of cellular immunotherapies based in competences in molecular biology / vectorology, viral supernatant production, cell and gene engineering in closed system GMP compliant (Good Manufacturing Process), integration of the validation processes for regulatory reviews by ANSM for clinical trial approval and biomonitoring of patients, have enabled me to develop strong translational research expertise applied in hematology and solid tumor.   The expertise acquired within the EFS led me to co-found the startup CanCell Therapeutics where I am managing director and head of translational research and development. Our aim is to develop, particularly in oncology, new Advanced Therapy Medicinal Products (ATMP) in the field of immunotherapy up to their commercialization.

Find also